UW spinout Icosavax raises $100M for vaccine development

Icosavax Inc., a biotech company focused on vaccine development, announced a $100M Series B investment round. Icosavax, a spinout from the University of Washington plans to use the funds to support clinical trials for its vaccine programs, which includes pursuing approvals for its COVID-19 vaccine candidate.

According to CEO Adam Simpson, “Based on preclinical data, we believe our vaccine candidates could offer significant protection against leading viral causes of pneumonia in older adults where no licensed vaccines currently exist.”

READ THE STORY at Puget Sound Business Journal »